Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons Open new browser tab
(2021)
Inizio contenuto principale del sito
(2021)
(2021)
(2021)
(2021)
(2021)
(2021)
(2021)
(2021)
(2021)
(2021)